RBC Capital maintains United Therapeutics at Outperform
RBC Capital reiterated a United Therapeutics rating of Outperform, according to Benzinga’s ratings-action roundup.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.
News Feed
2 results loaded, newest first. End of these results.
RBC Capital maintains United Therapeutics at Outperform
RBC Capital maintained its Outperform rating on United Therapeutics and raised its price target to $708 from $677.